trending Market Intelligence /marketintelligence/en/news-insights/trending/xK7W_j-BOI4oJQzQ70XTfQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

D&D Pharmatech obtains $137.1M in series B round

Gauging Supply Chain Risk In Volatile Times

Street Talk Episode 56 - Latest bank MOE shows even the strong need scale to thrive

South State CenterState MOE Shows Even The Strong Need Scale To Thrive

Talking Bank Stocks, Playing The M&A Trade With Longtime Investor

D&D Pharmatech obtains $137.1M in series B round

U.S.-based Octave Life Sciences and South Korean venture capital firm Smilegate Investment Inc. led a $137.1 million series B financing round for South Korean clinical-stage biotechnology company D&D Pharmatech Co. Ltd.

Current investors InterVest Co. Ltd., MAGNA Investment Co. Ltd. and LB Investment Inc. also participated in the round, together with individual shareholders/co-founders and employees from the U.S. and South Korea.

D&D Pharmatech focuses on the development and commercialization of revolutionary drugs through its three businesses Neuraly Inc., Precision Molecular Inc. and Theraly Fibrosis Inc.

Neuraly will use the capital to move a clinical candidate targeting neurodegenerative diseases into phase II trials, while Precision will use the funding to advance several neuroinflammation imaging agents into phase I and phase II trials. The capital will aid Theraly in advancing a preclinical candidate targeting fibrosis into a phase I/II trial.

D&D Pharmatech raised about $18.5 million in a series A round in March 2018, according to S&P Global Market Intelligence data.